Polyganics (Groningen, Netherlands) announced recently that it has signed an agreement with Synovis Micro Companies Alliance (Birmingham, Ala.) to become the exclusive distributor of its nerve capping device the NeuroCap in the U.S.
The new distribution agreement with Synovis will cover the entire U.S. and will help Polyganics meet its growing distribution demand for the NeuroCap device.
“We are committed to providing the latest surgical innovations to our customers, and Polyganics’s NeuroCap ideally complements our existing portfolio of peripheral nerve repair products,” said Michael Campbell, president of Synovis. “We look forward to working with Polyganics to enable reliable access to NeuroCap across the U.S. and help surgeons provide patients with the best care possible.”
NeuroCap is a treatment option for end-neuromas that happens at the end of a nerve that develops as a result of trauma. The device is made using Polyganics’s unique synthetic, transparent polymer and protects peripheral nerve ends and separates it from the environment to prevent any further damage and pain. It is used as an alternative to complex surgical procedures.
“The clinically proven NeuroCap device provides a unique solution to the pain experience by patients due to nerve damage. We continue to strengthen and expand the evidence for NeuroCap with ongoing clinical studies,” Rudy Mareel, CEO of Polyganics, said. “The initial interest in the product has been promising and we are now expanding our NeuroCap distribution network in the U.S. to improve efficiency of delivery and consistency of product availability for surgeons and patients. We are pleased to be working with Synovis MCA with their renowned expertise and established sales networks within the sectors.”
